TNON · XBRL financial data
Tenon Medical financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (TNON's year ends in late December)
- † Share count changed about 1/17 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (TNON's year ends in late December)
- † Share count changed about 1/17 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (TNON's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | †Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (3,332) | (3,134)* | (3,576) | (3,826) | (3,184) | (3,087)* | (3,616) | (2,769) | (3,339) | (2,832)* | (3,476) | (4,050) |
| Stock-based compensation | 1,070* | 981* | 1,018 | 1,034* | 910* | 883* | 872 | 417* | 58* | 344* | 331 | 412* |
| Depreciation and amortization | 46* | 93* | 100 | 89* | 102* | — | — | — | — | — | — | — |
| Net cash from operating activities | (3,153)* | (2,278)* | (2,338) | (2,420)* | (2,343)* | (2,777)* | (2,483) | (2,214)* | (3,824)* | (2,224)* | (2,960) | (2,758)* |
| Purchases of property and equipment | 57* | 92* | 119 | 0* | 104* | (37)* | — | — | (111)* | 192* | 56 | 172* |
| Net cash from investing activities | 436* | (92)* | (119) | 0* | (104)* | 37* | — | — | (639)* | (192)* | (56) | (172)* |
| Proceeds from issuing common stock | 0* | 0* | 1,934 | 0* | 172* | 0* | — | — | — | — | — | — |
| Proceeds from issuing equity | — | — | — | — | — | — | 4,010 | 0* | — | — | — | — |
| Net cash from financing activities | 266* | 1,371* | 4,371 | 0* | 9,641* | 113* | 6,259 | (59)* | 59* | 2,730* | 3,867 | 0* |
| Net change in cash | (2,481)* | (943)* | 1,960 | (2,420)* | 7,194* | (2,627)* | 3,776 | (2,465)* | (4,404)* | 314* | 851 | (2,930)* |
- † Share count changed about 1/17 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Tenon Medical | 1,677 | 1,279 | (2,758)* | 667,047 | 0.6 quarters | 10-QJun 30, 2026 |
| SeaStar Medical Holding | 6,959 | 615 | (2,994)* | 4.4M | 2.3 quarters | 10-QJun 30, 2026 |
| ENvue Medical | 1,084 | 239 | (2,691)* | 11.1M | 0.4 quarters | 10-QJun 30, 2026 |
| Bone Biologics | 6,088 | not reported | (532)* | 3.4M | 9.8 quarters | 10-QSep 30, 2026 |
| Sintx Technologies | 3,590 | 452 | (2,767)* | 6.7M | 1.3 quarters | 10-QJun 30, 2026 |
| OSR Health | 1,500 | 316 | (2,421)* | 35.1M | 0.6 quarters | 10-QJun 30, 2026 |
| Adm Tronics Unlimited | 223 | not reported | (33) | 67.6M | 6.8 quarters | 10-QJun 30, 2026 |
| Retractable Technologies | 2,641 | 7,201 | (1,732)* | 29.9M | 1.5 quarters | 10-QJun 30, 2026 |
| Sonoma Pharmaceuticals | 5,338 | 6,406 | (649) | 4.8M | 8.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.